- Home
- RS vs INAB Comparison
RS vs INAB Comparison
Compare RS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RS | INAB |
|---|---|---|
| Founded | 1939 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 10.6M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RS | INAB |
|---|---|---|
| Price | $299.36 | $1.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $317.25 | $108.00 |
| AVG Volume (30 Days) | ★ 315.4K | 55.7K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.63 | N/A |
| Revenue | ★ $13,922,300,000.00 | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | $21.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $250.07 | $1.45 |
| 52 Week High | $347.44 | $12.53 |
Technical Indicators
Market Signals| Indicator | RS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 70.23 | 32.34 |
| Support Level | $284.91 | $1.73 |
| Resistance Level | $295.00 | $1.87 |
| Average True Range (ATR) | 6.25 | 0.11 |
| MACD | 1.69 | -0.03 |
| Stochastic Oscillator | 98.70 | 1.50 |
Price Performance
Historical ComparisonAbout RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.